日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer.

JNK通路抑制介导ER+乳腺癌对联合内分泌治疗和CDK4/6抑制剂的不敏感性

Alexandrou Sarah, Lee Christine S, Fernandez Kristine J, Wiharja Celine E, Eshraghi Leila, Reeves John, Reed Daniel A, Portman Neil, Phan Zoe, Milioli Heloisa H, Nikolic Iva, Cadell Antonia L, Croucher David R, Simpson Kaylene J, Lim Elgene, Hickey Theresa E, Millar Ewan K A, Alves Carla L, Ditzel Henrik J, Caldon C Elizabeth

Deciphering Breast Tumor Heterogeneity Through Patient-Derived Organoids and Circulating Tumor Cells

利用患者来源的类器官和循环肿瘤细胞解析乳腺肿瘤异质性

Policastro, Benedetta; Nissen, Nikoline; Alves, Carla L

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor

针对 PI3K、ER 和 CDK4/6 的三联疗法可抑制对氟维司群和 CDK4/6 或 PI3K 抑制剂耐药的 ER 阳性乳腺癌的生长。

Karimi, Leena; Alves, Carla L; Terp, Mikkel G; Tuttolomondo, Martina; Portman, Neil; Ehmsen, Sidse; Johansen, Lene E; Bak, Martin; Lim, Elgene; Ditzel, Henrik J

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer

针对ER+乳腺癌的PI3K/AKT/mTOR通路药物治疗

Alves, Carla L; Ditzel, Henrik J

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

出版商更正:CDK4/6 和 AKT 与内分泌疗法联合靶向可阻止 CDK4/6 抑制剂和内分泌疗法耐药性乳腺癌的进展

Alves, Carla L; Ehmsen, Sidse; Terp, Mikkel G; Portman, Neil; Tuttolomondo, Martina; Gammelgaard, Odd L; Hundebøl, Monique F; Kaminska, Kamila; Johansen, Lene E; Bak, Martin; Honeth, Gabriella; Bosch, Ana; Lim, Elgene; Ditzel, Henrik J

Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2- Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies

ER+/HER2-晚期乳腺癌对CDK4/6抑制剂联合内分泌治疗的耐药机制:生物标志物和潜在的新型治疗策略

Al-Qasem, Abeer J; Alves, Carla L; Ditzel, Henrik J